Literature DB >> 2827482

Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase.

D Shoupe1, D R Mishell, M A Page, H Madkour, I M Spitz, R A Lobo.   

Abstract

RU 486, a synthetic steroid with antiprogesterone receptor activity, was used to investigate the importance of progesterone on gonadotropin secretory dynamics in the midcycle of the normal menstrual cycle. Six normally cycling women were followed for three consecutive cycles. During each cycle, blood samples were obtained beginning on day 10 and continued until menses. After a control cycle, 100 mg RU 486 was given orally between days 10 and 17. The patients were followed for a posttreatment cycle with no medication. When RU 486 was given before the midcycle, the luteinizing hormone surge was delayed by 15.0 +/- 2.1 days after ingestion of the last pill, resulting in cycles of 40.6 +/- 2.6 compared with 28.0 +/- 2.3 days (p less than 0.01). During RU 486 administration and at the time a normal luteinizing hormone surge was anticipated, an attenuated luteinizing hormone/follicle-stimulating hormone surge was noted that was not followed by a rise in progesterone. After the attenuated surge a normal luteinizing hormone/follicle-stimulating hormone level occurred, with a normal rise in progesterone. Estradiol levels during RU 486 administration decreased during treatment, indicating a possible direct action of RU 486 on the ovary.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2827482     DOI: 10.1016/s0002-9378(87)80236-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

2.  Emergency contraception: potential role of ulipristal acetate.

Authors:  Kristina Gemzell-Danielsson; Chun-Xia Meng
Journal:  Int J Womens Health       Date:  2010-08-09

3.  Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914.

Authors:  Pamela Stratton; Eric D Levens; Beth Hartog; Johann Piquion; Qingxiang Wei; Maria Merino; Lynnette K Nieman
Journal:  Fertil Steril       Date:  2009-02-06       Impact factor: 7.329

4.  The Neurosteroid Progesterone Underlies Estrogen Positive Feedback of the LH Surge.

Authors:  Paul Micevych; Kevin Sinchak
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-02       Impact factor: 5.555

Review 5.  Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Flavia A Cimini; Ilaria Barchetta; Simone Carotti; Laura Bertoccini; Marco G Baroni; Umberto Vespasiani-Gentilucci; Maria-Gisella Cavallo; Sergio Morini
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

Review 6.  Control of oocyte release by progesterone receptor-regulated gene expression.

Authors:  Rebecca L Robker; Lisa K Akison; Darryl L Russell
Journal:  Nucl Recept Signal       Date:  2009-12-31

7.  Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia.

Authors:  Hongmei Zhu; Xuchen Jia; Mingli Ren; Liguo Yang; Jianguo Chen; Li Han; Yi Ding; Mingxing Ding
Journal:  Front Cell Dev Biol       Date:  2020-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.